Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Curr Opin HIV AIDS. 2013 Jul;8(4):326-32. doi: 10.1097/COH.0b013e328361d178.
In this review, examples of recent progress in HIV-1 vaccine research are discussed.
New insights from the immune correlates analyses of the RV144 efficacy trial have accelerated vaccine development with leads to follow in nonhuman primate studies and improved vaccine designs. Several new vaccine vector approaches offer promise in the exquisite control of acute infection and in improving the breadth of T-cell responses. New targets of broadly neutralizing antibodies (BnAbs) have been elucidated, and improved understanding of how the human host controls BnAb development have emerged from BnAb knock-in mice and from analyses of BnAb maturation and virus evolution in individuals followed from the time of HIV-1 transmission to BnAb induction.
Based on these observations, it is clear that the development of a successful HIV-1 vaccine will require new vaccine approaches and iterative testing of immunogens in well designed animal and human trials.
在这篇综述中，讨论了 HIV-1 疫苗研究的最新进展实例。
从 RV144 功效试验的免疫相关性分析中获得的新见解加速了疫苗的开发，为后续的非人类灵长类动物研究和改进的疫苗设计提供了线索。几种新的疫苗载体方法在急性感染的精确控制和提高 T 细胞反应的广度方面有希望。已经阐明了广谱中和抗体 (BnAb) 的新靶点，并且通过 BnAb 基因敲入小鼠以及对个体从 HIV-1 传播到 BnAb 诱导期间的 BnAb 成熟和病毒进化的分析，对人类宿主如何控制 BnAb 发展有了更深入的了解。
基于这些观察结果，很明显，开发成功的 HIV-1 疫苗将需要新的疫苗方法，并在精心设计的动物和人体试验中反复测试免疫原。
